GlassScriptPhysician profile
John C Gollier
NPI 1104857911
$10,514.83
in general payments reported to CMS, 2019-2025
60 companies · $1,769 in 2025
The $1,769 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,045 · 2020: $882 · 2021: $1,768 · 2022: $1,735 · 2023: $1,853 · 2024: $1,463 · 2025: $1,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,085.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,318.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,144.69 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,089.92 | 2021-2025 | |
| Lilly USA, LLC | $950.95 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $804.97 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $393.18 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $387.57 | 2019-2025 | Jardiance, Stiolto Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $346.42 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $307.16 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Otsuka America Pharmaceutical, INC. | $254.60 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $246.83 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $198.61 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $196.42 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $190.12 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Daiichi Sankyo INC. | $173.02 | 2020-2022 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gollier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.